Objectives: Anemia during pregnancy is characterized by hemoglobin concentration <11 g/dl in pregnant women, which decreases oxygen carrying capacity of the blood to the body tissues. It is estimated that worldwide 41.8% of pregnant and 30.2% of non-pregnant women are anemic. This study aims to determine the prevalence and factors associated with anemia in pregnant women attending antenatal clinic at our tertiary care center. Materials and Methods: A cross-sectional observational study was conducted among 500 pregnant women attending antenatal clinic for the 1st time in the Department of Obstetrics and Gynaecology, AIMSR, Bathinda, for a period of 1 year. The hemoglobin was measured using automated cell counter method and those with hemoglobin level <11 g/dl were considered as anemic and were investigated further to be assessed according to the Indian Council of Medical Research classification. Data were collected using predesigned and pretested structured questionnaire. Results: The mean Hb concentration was 9.06 g/dl among the anemic group. Overall prevalence of anemia among pregnant women was found to be 408 (81.8%). Residence, educational status, monthly family income, occupation, gestational age, iron folic acid supplementation, dietary habits of not eating green leafy vegetables, meat and animal products, and drinking tea and coffee immediately after meal were the variables which had statistically significant association with the prevalence of anemia. Conclusion: Anemia control program should be executed more resourcefully in this vital segment of population. Awareness of above said factors is more important to prevent anemia rather than early diagnosis and treatment.
Background: The placenta provides the physiologic link between a pregnant woman and the fetus. During pregnancy, the normal placenta increases its thickness at a rate of approximately 1 millimeter per week. The thickness is considered normal throughout the 2nd and 3rd trimester if between 2 and 4 cm. There is a need to identify the fetus failing to reach its growth potential because an early detection of intrauterine growth retardation will be beneficial to obstetric and neonatal care.Methods: After applying inclusion and exclusion criteria, 251 antenatal women from 24-39 weeks gestation were included in the study. After informed written consent, relevant history, examination, abdominal ultrasound was performed noting fetal biometry and placental thickness. The participants were followed until delivery and birth weight noted. Statistical analysis of birth weight (< and >2500 gm) with placental thickness was done.Results: Mean age of the study was 25.88±4.34 years. The mean placental thickness in group A was 3.33±0.92 cm and in group B was 3.38±0.68 cm. Placental thickness showed a positive correlation with fetal weight (r=0.013), however it was not statistically significant. Uncomplicated pregnancy group had mean placental thickness of 3.40±0.70 cm. The difference of mean for placental thickness was statistically significant with respect to medical disorders (p=0.042).Conclusions: Placental thickness does increase with increasing birth weight of the fetus and hence, subnormal or more than normal placental thickness is helpful in signalling important maternal conditions that may be detrimental to the fetus.
Connective tissue disorders (CTD) include a variety of chronic multisystem disorders including autoimmune conditions. Many of these conditions affect women of childbearing age and therefore pregnancy poses an important challenge for the caregivers. The precise knowledge of therapeutic safety and the effect of disease on pregnancy and vice versa are important to achieve best outcome. Hence, it is imperative to have a vast knowledge of disease with proper preconception counselling. We report series of cases of connective tissue disorders in pregnancy: tuberous sclerosis (TS), systemic lupus erythmatosis (SLE) and neurofibromatosis (NF) type 1. The first case with tuberous sclerosis was associated with obstetric complications. In both cases of SLE, we observed preterm delivery and IUGR. However, the course of SLE remained the same in both the cases. The case with NF 1 taught us that a normal obstetric outcome could be expected in pregnant women.
Background: The most frequent thyroid alteration observed in pregnancy is hypothyroidism with subclinical hypothyroidism being more common than overt hypothyroidism. Women with thyroid dysfunction both overt and subclinical are at increased risk of pregnancy-related complications. In present study we assessed feto-maternal outcome of pregnancies in whom hypothyroidism was diagnosed after 28 weeks of gestation.Methods: This study was conducted in the department of obstetrics and gynaecology, Adesh institute of medical sciences and research Medical College, Bathinda. The present study was of prospective, observational design, conducted in pregnant women with more than 28 weeks pregnancy, first time diagnosed as hypothyroid (TSH>3.0 mIU/l).Results: In present study total 37 patients completed study protocol, 6 patients were delivered at other hospital. Most patients were less than 20 years (32%), nulliparous (68%). 19% patients delivered preterm either due to spontaneous labour or labour induction for obstetric reason. 62% patients delivered vaginally, 35% underwent LSCS. In present study maternal complications such as preterm labour (24%), hypertensive disorders of pregnancy (22%), oligohydramnios (16%), overt/gestational diabetes mellitus (8%) and post-partum haemorrhage (5%) were noted. 2.5-3.4 kg birth weight was most common group (65%). Total 16 % babies required neonatal resuscitation. Babies requiring neonatal resuscitation were admitted in NICU for observation and for any further management. Neonatal jaundice was noted in 30% babies. Total 22% babies needed NICU admission. We noted early neonatal death in one baby. No maternal mortality was noted.Conclusions: Treatment of maternal hypothyroidism is essential, because adverse outcomes for both mother and baby are greatly reduced, if not eliminated, when patients are treated.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.